NeuroPace (NPCE) Net Equity Issued and Repurchased (2024 - 2025)

NeuroPace's (NPCE) quarterly Net Equity Issued and Repurchased came in at $69.4 million in Q4 2025, up 199.13% quarter-over-quarter from -$70.0 million in Q2 2025.

NeuroPace (NPCE) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends

NeuroPace's Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $69.4 million for Q4 2025.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $69.4 million in Q4 2025; TTM through Mar 2026 was -$611000.0, a 100.83% decrease from a year earlier, with the FY2025 full-year figure at $69.7 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased improved to $69.4 million in Q4 2025 per NPCE's latest filing, from -$70.0 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $70.3 million in Q1 2025 and bottomed at -$70.0 million in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 NeuroPace 494.96 Mn 440.98 Mn 18.05 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 69.42 Mn
Dec 31, 2025 69.42 Mn
Jun 30, 2025 -70.03 Mn
Jun 30, 2025 -70.03 Mn
Mar 31, 2025 70.27 Mn
Mar 31, 2025 70.27 Mn
Sep 30, 2024 3.00 Mn
Sep 30, 2024 3.00 Mn